Sant Kumar Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sant Kumar Verma has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Ghanshyam Das Gupta
19 shared publicationsRupali Kohal
Department of Pharmaceutical Chemistry & Analysis, ISF College of Pharmacy, Moga 142 001 Punjab, India
10 shared publicationsPreety Kumari
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga-142 001, Punjab, India
5 shared publicationsPriya Bisht
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, Punjab, India
5 shared publicationsShalini Jaswal
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga-142 001, Punjab, India
5 shared publications- Suresh Thareja
Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda,Punjab 151401, India
4 shared publications
Latest Publications
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Organic Chemistry
- Vol. 24
Green Approaches for the Synthesis of Bioactive Molecules: Recent Advances and Sustainable Alternatives to Conventional Methods
Faster, cleaner, and more energy-efficient green methodologies, such as microwaveassisted, ultrasound-assisted, and metal-free catalysis, are legitimate approaches to synthesizing bioactive molecules. These sustainable techniques have demonstrated considerable improvements in atom economy, reduced energy consumption, shortened reaction times, and minimized waste. The review focuses on recent progress in the preparation of bioactive molecules using greener approaches, including microwave- and ultrasound-assisted methods and metal-free catalysis, compared with conventional techniques. Various important reactions, including Knoevenagel condensation, Huisgen cycloaddition, Suzuki coupling, Stobbe condensation, Claisen-Schmidt condensation, Fischer esterification, Pictet-Spengler reaction, and Biginelli condensation, have been elaborated in terms of reaction feasibility, product recovery, and yield for the synthesis of diverse heterocyclic scaffolds such as coumarin, thiazoles, triazole, pyrazole, benzimidazole, and pyrimidine, demonstrating a broad range of pharmacological activities, anticancer, antiviral, antimicrobial, antileishmanial, antiinflammatory, CNS modulating agents, and other miscellaneous agents. Mechanistic insight into microwave heating, acoustic cavitation, photocatalytic, organocatalytic, and enzymatic transformations emphasizes their effectiveness in enabling green and efficient synthesis. Future directions, including the importance of continuous-flow reactor systems, sensor technologies, feedback control, the hybridization of green approaches, and the use of AI-driven matrices, have been explored to gain further insights. These developments highlight the importance of environmentally friendly synthesis of pharmaceuticals and bioactive compounds.
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Organic Chemistry
- Vol. 24
Green Approaches for the Synthesis of Bioactive Molecules: Recent Advances and Sustainable Alternatives to Conventional Methods
Faster, cleaner, and more energy-efficient green methodologies, such as microwaveassisted, ultrasound-assisted, and metal-free catalysis, are legitimate approaches to synthesizing bioactive molecules. These sustainable techniques have demonstrated considerable improvements in atom economy, reduced energy consumption, shortened reaction times, and minimized waste. The review focuses on recent progress in the preparation of bioactive molecules using greener approaches, including microwave- and ultrasound-assisted methods and metal-free catalysis, compared with conventional techniques. Various important reactions, including Knoevenagel condensation, Huisgen cycloaddition, Suzuki coupling, Stobbe condensation, Claisen-Schmidt condensation, Fischer esterification, Pictet-Spengler reaction, and Biginelli condensation, have been elaborated in terms of reaction feasibility, product recovery, and yield for the synthesis of diverse heterocyclic scaffolds such as coumarin, thiazoles, triazole, pyrazole, benzimidazole, and pyrimidine, demonstrating a broad range of pharmacological activities, anticancer, antiviral, antimicrobial, antileishmanial, antiinflammatory, CNS modulating agents, and other miscellaneous agents. Mechanistic insight into microwave heating, acoustic cavitation, photocatalytic, organocatalytic, and enzymatic transformations emphasizes their effectiveness in enabling green and efficient synthesis. Future directions, including the importance of continuous-flow reactor systems, sensor technologies, feedback control, the hybridization of green approaches, and the use of AI-driven matrices, have been explored to gain further insights. These developments highlight the importance of environmentally friendly synthesis of pharmaceuticals and bioactive compounds.
- 14 August 2026
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part A
- Vol. 61 (12) , 1211-1225
Remediation of polyvinyl chloride from water by UV/sulfate radical-based advanced oxidation process
Poor degradability and the widespread use of plastics have made plastic pollution a major environmental concern, particularly in water bodies. When plastic breaks up in the environment, pieces less...
- 14 August 2026
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part A
- Vol. 61 (12) , 1211-1225
Remediation of polyvinyl chloride from water by UV/sulfate radical-based advanced oxidation process
Poor degradability and the widespread use of plastics have made plastic pollution a major environmental concern, particularly in water bodies. When plastic breaks up in the environment, pieces less...
- 24 February 2026
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 198
An expedition on paper-based microfluidic point-of-care testing devices for the detection of infectious diseases
- 24 February 2026
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 198
An expedition on paper-based microfluidic point-of-care testing devices for the detection of infectious diseases
- 10 February 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1773, 466785
Recent developments in sorbent-based microextraction techniques for the processing of complex matrices
- 10 February 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1773, 466785
Recent developments in sorbent-based microextraction techniques for the processing of complex matrices
- 4 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (3) , 1445-1473
Medicinal attributes of nitrogen heterocycles directing aldose reductase selectivity and potency
This review describes the medicinal attributes of nitrogen heterocycles, including SAR and target-interaction studies that guide their selectivity and potency for aldose reductase.
- 4 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (3) , 1445-1473
Medicinal attributes of nitrogen heterocycles directing aldose reductase selectivity and potency
This review describes the medicinal attributes of nitrogen heterocycles, including SAR and target-interaction studies that guide their selectivity and potency for aldose reductase.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Integrated 3D-QSAR, molecular docking, molecular dynamics, DFT, in vitro , and in vivo evaluation of benzylidene-thiazolidinedione derivatives as aldose reductase inhibitors
A benzylidene-thiazolidinedione derivative (SA02) has been discovered as a promising lead aldose reductase inhibitor with good antidiabetic potential.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Integrated 3D-QSAR, molecular docking, molecular dynamics, DFT, in vitro , and in vivo evaluation of benzylidene-thiazolidinedione derivatives as aldose reductase inhibitors
A benzylidene-thiazolidinedione derivative (SA02) has been discovered as a promising lead aldose reductase inhibitor with good antidiabetic potential.
- 29 November 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (11) , e70159
C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights
Diabetic complications are major health problems that happen to people with diabetes when their blood sugar levels stay high for a long time and damage various body organs and systems. Inhibition of aldose reductase has emerged as a promising strategy for drug development and the management of diabetes‐associated complications. In the research article, a novel series of 12 compounds, “ C −5‐arylidene thiazolidine‐2,4‐dione derivatives” was constructed, synthesized, and characterized using both spectral and non‐spectral techniques. The confirmed synthesized compounds were subsequently screened for in vitro aldose reductase inhibitory activity. Among them, compounds 9h and 9a exhibited superior potency against aldose reductase protein with IC 50 values of 0.98 and 1.05 µM, respectively, as compared with the reference drug epalrestat (IC 50 value of 1.20 µM). Additionally, compounds 9l and 9i showed moderate aldose reductase inhibitory activity with an IC 50 value of 1.36 and 2.47 µM, respectively. Furthermore, the top four best active compounds were selected for in vivo anti‐hyperglycaemic activity. Results revealed that all the tested compounds significantly decreased blood glucose levels at all time intervals. Computational analysis revealed that all synthesized candidates bound firmly in the protein cavity of aldose reductase via hydrogen bonds and steric interaction with the range of docking score −10.21 to −11.81 kcal/mol. Predicted in silico toxicity data suggested that the synthesized compounds were inactive and nontoxic against peroxisome proliferator‐activated receptor‐γ protein. These finding results support the potential of thiazolidine‐2,4‐dione derivatives as promising AR inhibitors for managing diabetic complications.
- 29 November 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (11) , e70159
C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights
Diabetic complications are major health problems that happen to people with diabetes when their blood sugar levels stay high for a long time and damage various body organs and systems. Inhibition of aldose reductase has emerged as a promising strategy for drug development and the management of diabetes‐associated complications. In the research article, a novel series of 12 compounds, “ C −5‐arylidene thiazolidine‐2,4‐dione derivatives” was constructed, synthesized, and characterized using both spectral and non‐spectral techniques. The confirmed synthesized compounds were subsequently screened for in vitro aldose reductase inhibitory activity. Among them, compounds 9h and 9a exhibited superior potency against aldose reductase protein with IC 50 values of 0.98 and 1.05 µM, respectively, as compared with the reference drug epalrestat (IC 50 value of 1.20 µM). Additionally, compounds 9l and 9i showed moderate aldose reductase inhibitory activity with an IC 50 value of 1.36 and 2.47 µM, respectively. Furthermore, the top four best active compounds were selected for in vivo anti‐hyperglycaemic activity. Results revealed that all the tested compounds significantly decreased blood glucose levels at all time intervals. Computational analysis revealed that all synthesized candidates bound firmly in the protein cavity of aldose reductase via hydrogen bonds and steric interaction with the range of docking score −10.21 to −11.81 kcal/mol. Predicted in silico toxicity data suggested that the synthesized compounds were inactive and nontoxic against peroxisome proliferator‐activated receptor‐γ protein. These finding results support the potential of thiazolidine‐2,4‐dione derivatives as promising AR inhibitors for managing diabetic complications.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 21 (8) , 901-922
A Review on Advancement in Analytical Quality by Design (AQbD)
Analytical Quality by Design (AQbD) represents a transformative methodology in pharmaceutical development, anchored in a systematic, risk-based, and data-driven framework. This approach optimizes analytical methods, fostering heightened product quality, efficient regulatory compliance, and informed decision-making. The industry's increasing acceptance of AQbD principles signifies a paradigm shift towards enhanced efficiency, sustainability, and global harmonization. This review comprehensively explores AQbD principles, regulatory perspectives, and its applications, particularly in analytical method development, including high-performance liquid chromatography (HPLC) and high-performance thin-layer chromatography (HPTLC). Emphasis is placed on the symbiotic relationship between AQbD and analytical method validation (AMV), elucidating their collective role in ensuring reliable and accurate analytical results. Integrating AQbD in method transfer, automation, and control strategies underscores its pivotal role in achieving robust, efficient, and compliant analytical processes. The review delves into lifecycle management and continuous improvement, coupled with AQbD principles, ensuring sustained method reliability throughout the pharmaceutical product lifecycle. AQbD's significant contribution to pharmaceutical lifecycle management, optimization, and change control is explored, emphasizing its systematic, data-driven, and risk-based approach to method development, validation, and ongoing enhancement. This review illuminates AQbD's transformative impact on pharmaceutical analysis, aligning with industry trends toward quality, efficiency, and regulatory compliance.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 21 (8) , 901-922
A Review on Advancement in Analytical Quality by Design (AQbD)
Analytical Quality by Design (AQbD) represents a transformative methodology in pharmaceutical development, anchored in a systematic, risk-based, and data-driven framework. This approach optimizes analytical methods, fostering heightened product quality, efficient regulatory compliance, and informed decision-making. The industry's increasing acceptance of AQbD principles signifies a paradigm shift towards enhanced efficiency, sustainability, and global harmonization. This review comprehensively explores AQbD principles, regulatory perspectives, and its applications, particularly in analytical method development, including high-performance liquid chromatography (HPLC) and high-performance thin-layer chromatography (HPTLC). Emphasis is placed on the symbiotic relationship between AQbD and analytical method validation (AMV), elucidating their collective role in ensuring reliable and accurate analytical results. Integrating AQbD in method transfer, automation, and control strategies underscores its pivotal role in achieving robust, efficient, and compliant analytical processes. The review delves into lifecycle management and continuous improvement, coupled with AQbD principles, ensuring sustained method reliability throughout the pharmaceutical product lifecycle. AQbD's significant contribution to pharmaceutical lifecycle management, optimization, and change control is explored, emphasizing its systematic, data-driven, and risk-based approach to method development, validation, and ongoing enhancement. This review illuminates AQbD's transformative impact on pharmaceutical analysis, aligning with industry trends toward quality, efficiency, and regulatory compliance.
- 3 July 2025
- Published by Elsevier in Fitoterapia
- Vol. 185, 106716
Insights to phytochemistry, analytical methods, pharmacological activities, stability, and specifications of alantolactone
- 3 July 2025
- Published by Elsevier in Fitoterapia
- Vol. 185, 106716
Insights to phytochemistry, analytical methods, pharmacological activities, stability, and specifications of alantolactone
- 5 June 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (22)
Pyrimidine‐2,4‐dione‐Based DPP‐4 Inhibitors: A Structure‐Guided Multifaced 3D‐QSAR and Molecular Dynamics Studies
DPP‐4 inhibitors have demonstrated efficacy in preventing incretin degradation, offering therapeutic potential for managing type 2 diabetes mellitus. Pyrimidine‐2,4‐dione‐based compounds have been identified as promising DPP‐4 inhibitors, exemplified by the approved drug alogliptin. This study conducted structure‐guided alignment‐dependent Gaussian field‐ and atom‐based 3D‐QSAR analyzes on a dataset of 103 molecules. The robustness and predictive accuracy of the developed multifaceted 3D‐QSAR models were evaluated using diverse statistical parameters, confirming their reliability. Favorable and unfavorable pharmacophoric features were mapped for each 3D‐QSAR model. A five‐point common pharmacophore hypothesis was generated. Molecular dynamics (MD) simulations, extending up to 100 ns, were performed for a potent compound (compound 92) from the dataset and compared to the reference drug alogliptin. MD simulation data highlight the stability of the investigated ligand‐target complexes and provide insights into the binding energy. The stability outcomes obtained from molecular dynamics simulations offer valuable guidance for the structure‐based design of novel pyrimidine‐2,4‐dione derivatives with improved selectivity toward DPP‐4. In addition, the pharmacophore hypothesis developed in this study serves as a reliable template for designing a refined chemical library comprising molecules with optimized DPP‐4 inhibitory activity, which could contribute to the designing of newer therapeutic candidates for type 2 diabetes management.
- 5 June 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (22)
Pyrimidine‐2,4‐dione‐Based DPP‐4 Inhibitors: A Structure‐Guided Multifaced 3D‐QSAR and Molecular Dynamics Studies
DPP‐4 inhibitors have demonstrated efficacy in preventing incretin degradation, offering therapeutic potential for managing type 2 diabetes mellitus. Pyrimidine‐2,4‐dione‐based compounds have been identified as promising DPP‐4 inhibitors, exemplified by the approved drug alogliptin. This study conducted structure‐guided alignment‐dependent Gaussian field‐ and atom‐based 3D‐QSAR analyzes on a dataset of 103 molecules. The robustness and predictive accuracy of the developed multifaceted 3D‐QSAR models were evaluated using diverse statistical parameters, confirming their reliability. Favorable and unfavorable pharmacophoric features were mapped for each 3D‐QSAR model. A five‐point common pharmacophore hypothesis was generated. Molecular dynamics (MD) simulations, extending up to 100 ns, were performed for a potent compound (compound 92) from the dataset and compared to the reference drug alogliptin. MD simulation data highlight the stability of the investigated ligand‐target complexes and provide insights into the binding energy. The stability outcomes obtained from molecular dynamics simulations offer valuable guidance for the structure‐based design of novel pyrimidine‐2,4‐dione derivatives with improved selectivity toward DPP‐4. In addition, the pharmacophore hypothesis developed in this study serves as a reliable template for designing a refined chemical library comprising molecules with optimized DPP‐4 inhibitory activity, which could contribute to the designing of newer therapeutic candidates for type 2 diabetes management.